2seventy bio Inc (NAS:TSVT)

$ 4.51 0.11 (2.5%) Market Cap: 231.84 Mil Enterprise Value: 297.88 Mil PE Ratio: 0 PB Ratio: 1.09 GF Score: 46/100

Q1 2024 2Seventy Bio Inc Earnings Call Transcript
May 08, 2024

$4.48 (-9.68%)

Earnings
Q4 2023 2Seventy Bio Inc Earnings Call Transcript
Mar 05, 2024

$5.79 (+6.83%)

Earnings
2Seventy Bio Inc Investor Call Transcript
Dec 12, 2023
Q3 2023 2Seventy Bio Inc Earnings Call Transcript
Nov 14, 2023

$2.28 (+0.88%)

Earnings
2Seventy Bio Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2023
2Seventy Bio Inc Conference Call Transcript
Sep 12, 2023
Q2 2023 2Seventy Bio Inc Earnings Call Transcript
Aug 14, 2023

$6.03 (+1.34%)

Earnings
2seventy bio, Inc. Presents at Goldman Sachs 44th Annual Global Healthcare Conference, Jun-14-2023 03:20 PM Transcript
Jun 14, 2023
2Seventy Bio Inc R&D Deep Dive Presentation (Virtual) Transcript
May 19, 2023
Q1 2023 2Seventy Bio Inc Earnings Call Transcript
May 03, 2023

$10.05 (-1.28%)

Earnings
Atara Biotherapeutics Inc, Cellectis SA and 2Seventy Bio Inc at Citi BioPharma Conference- Panel Transcript
Sep 07, 2022
Q2 2022 2Seventy Bio Inc Earnings Call Transcript
Aug 10, 2022

$17.22 (+3.11%)

Earnings
2Seventy Bio Inc Focus on bNHL and Solid Tumor Strategy Conference Call Transcript
Sep 22, 2021
2Seventy Bio Inc Introduction to 2seventy's Pipeline and Next-Gen Multiple Myeloma Strategy Conference Call Transcript
Sep 21, 2021

Q1 2024 2Seventy Bio Inc Earnings Call Transcript

May 08, 2024 / 12:00PM GMT

Release Date Price: $4.48 (-9.68%)

Transcript 8-K

Operator

Good day and thank you for standing by. Welcome to the 2Seventy Bio first quarter 2024 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Jenn Snyder with 2Seventy Bio. Please go ahead.

Jenn Snyder

2Seventy Bio Inc - SVP, Corporate Affairs

Thank you, Shannon, and good morning, everyone. Thank you for joining us. This morning, we issued a press release on our first quarter 2024 financial results. The press release can be found in the Investors and Media section of the company's website at 2seventybio.com.

As a reminder, today's discussion will include forward-looking statements related 2Seventy Bio's current plans and expectations, which are subject to certain risks and uncertainties.

These forward-looking statements regarding regarding our strategic plans, timelines and expectations with respect to sales, efficacy and perceived therapeutic benefits of Abecma, the timing and review of additional studies and

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.